➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Johnson and Johnson
Medtronic
Mallinckrodt

Last Updated: March 1, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for VS-6063

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for VS-6063?

VS-6063 is an investigational drug.

There have been 16 clinical trials for VS-6063. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2020.

The most common disease conditions in clinical trials are Mesothelioma, Ovarian Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), and Cancer Research UK.

There are fifteen US patents protecting this investigational drug and one hundred and twenty-six international patents.

Recent Clinical Trials for VS-6063
TitleSponsorPhase
Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal MelanomaVerastem, Inc.Phase 2
Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal MelanomaThomas Jefferson UniversityPhase 2
A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung CancerVerastem, Inc.Phase 2

See all VS-6063 clinical trials

Clinical Trial Summary for VS-6063

Top disease conditions for VS-6063
Top clinical trial sponsors for VS-6063

See all VS-6063 clinical trials

US Patents for VS-6063

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VS-6063   Start Trial Gene fusions and gene variants associated with cancer LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)   Start Trial
VS-6063   Start Trial Methods of diagnosing and treating B cell acute lymphoblastic leukemia The General Hospital Corporation (Boston, MA) Tufts Medical Center, Inc. (Boston, MA)   Start Trial
VS-6063   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
VS-6063   Start Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Start Trial
VS-6063   Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA)   Start Trial
VS-6063   Start Trial Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN)   Start Trial
VS-6063   Start Trial Use of facilitates chromatin transcription complex (FACT) in cancer Incuron, Inc. (Buffalo, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VS-6063

Drugname Country Document Number Estimated Expiration Related US Patent
VS-6063 Australia AU2014254394 2033-04-17   Start Trial
VS-6063 China CN105378110 2033-04-17   Start Trial
VS-6063 China CN106414768 2033-04-17   Start Trial
VS-6063 European Patent Office EP2986736 2033-04-17   Start Trial
VS-6063 European Patent Office EP3122901 2033-04-17   Start Trial
VS-6063 European Patent Office EP3438288 2033-04-17   Start Trial
VS-6063 Japan JP2016518123 2033-04-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Johnson and Johnson
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.